[A23-142] Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V
Last updated 02.04.2024
Project no.:
A23-142
Commission:
Commission awarded on 20.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Children and adolescents aged 10 to 17 years with type 2 diabetes mellitus who have not achieved sufficient blood glucose control with their previous drug therapy consisting of at least one blood glucose-lowering drug as an adjunct to diet and exercise
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A23-142_en
| Project no. | Title | Status |
|---|---|---|
| A16-46 | Empagliflozin - Addendum to Commission A16-12 | Commission completed |
| A14-26 | Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A16-12 | Empagliflozin - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-78 | Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A22-39 | Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-93 | Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V | Commission completed |